Schering Continues To Feel Symptoms From Claritin Switch With Net Loss

Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings